# Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

Study · id `cardio:ct-nct06969807` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06969807](<https://clinicaltrials.gov/study/NCT06969807>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06969807

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06969807. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-09 (actual); primary completion 2026-08-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06969807, source copy `cardio:ctgov-nct06969807-2026-07-14`, retrieved 2026-10-26)
- Started: 2025-06-09 (actual) (ClinicalTrials.gov record NCT06969807, source copy `cardio:ctgov-nct06969807-2026-07-14`, retrieved 2026-10-26)
- Primary completion: 2026-08-15 (anticipated) (ClinicalTrials.gov record NCT06969807, source copy `cardio:ctgov-nct06969807-2026-07-14`, retrieved 2026-10-26)
- Completion: 2028-05-15 (anticipated) (ClinicalTrials.gov record NCT06969807, source copy `cardio:ctgov-nct06969807-2026-07-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06969807, source copy `cardio:ctgov-nct06969807-2026-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06969807-2026-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
- Acronym: MSC-DKD-001
- Condition: Diabetic Kidney Disease (DKD)
- Intervention (Drug): Amimestrocel
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

## Provenance

Content hash: 2196f104603764f7cdd13cbf4c5ee8dffc23a27e0d30cc1c13a5d211795720d4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
